- Home
- MDAI vs ATYR Comparison
MDAI vs ATYR Comparison
Compare MDAI & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MDAI | ATYR |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.5M | 49.2M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MDAI | ATYR |
|---|---|---|
| Price | $1.57 | $0.50 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 9 |
| Target Price | $3.00 | ★ $3.67 |
| AVG Volume (30 Days) | 142.2K | ★ 590.9K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 65.88 | 6.98 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $19,650,000.00 | $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.18 | $0.40 |
| 52 Week High | $2.97 | $6.50 |
Technical Indicators
Market Signals| Indicator | MDAI | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 42.94 | 44.21 |
| Support Level | $1.49 | $0.46 |
| Resistance Level | $1.77 | $0.59 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 8.62 | 18.46 |
Price Performance
Historical ComparisonAbout MDAI Spectral AI Inc.
Spectral AI Inc is an AI company focused on predictive medical diagnostics. Its DeepView System uses proprietary AI algorithms to distinguish between fully damaged, partially damaged and healthy human tissue characters invisible to the naked eye, at the initial time point of wound presentation. The DeepView System delivers a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future. The company focuses on the burn indication which is supported by the BARDA PBS contract.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).